Securities Fraud Investigation Into Zynex, Inc. (ZYXI) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announces an investigation of Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) on behalf of investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON ZYNEX, INC. (ZYXI), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.

What Is The Investigation About?

On March 11, 2025, after market hours, Zynex released its fourth quarter and full year 2024 financial results, revealing a revenue “shortfall” in the quarter “due to slower than normal payments from certain payers.” The Company further revealed it has been “notified that Tricare has temporarily suspended payments as they review prior claims.” Tricare is the healthcare program for uniformed service members and “currently represents approximately 20-25% of [the Company’s] annual revenue.”

On this news, Zynex’s stock price fell $3.59, or 51.3%, to close at $3.41 per share on March 12, 2025, thereby injuring investors.

Contact Us To Participate or Learn More:

If you purchased Zynex securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

The Law Offices of Frank R. Cruz,

2121 Avenue of the Stars, Suite 800,

Century City, California 90067

Call us at: 310-914-5007

Email us at: info@frankcruzlaw.com

Visit our website at: www.frankcruzlaw.com.

Follow us for updates on Twitter at twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.